HK1 and ovarian carcinoma: Gain-of-function and loss-of-function in combination with in vivo analyses established that LINC00092 promoted ovarian cancer metastasis by binding with a glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 2 (PFKFB2), which proved to be critical for ovarian cancer metastasis and glycolytic phenotype, indicating that LINC00092 acted in ovarian cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer [116].